Fox Business - The Power to Prosper
Search Site

Amylin Pharmaceuticals

Related Topics

  1. King Pharmaceuticals
  2. Vertex Pharmaceuticals
  3. Pharmaceuticals
  4. Watson Pharmaceuticals
  5. Regeneron Pharmaceuticals
  6. Bristol-Myers Squibb
Get updates on Amylin Pharmaceuticals
Former Bristol-Myers executive admits to insider trading

A former Bristol-Myers Squibb Co finance executive on Monday pleaded guilty to an insider trading charge, admitting to buying stock options in a biotechnology company that the drugmaker was preparing to buy.Robert Ramnarine, 46, admitted to one count of securities fraud for trading in Amylin Pharmaceuticals Inc options before Bristol-Myers agreed to buy that company last June for $5.3 billion, U.S. Attorney Paul Fishman in New Jersey said.Federal prosecutors had last August charged Ramnarine with three counts of securities fraud.They said he made $311,361 of illegal profit from August 2010 to July 2012 from options trading in Amylin and two other companies that Bristol-Myers sought to buy - Pharmasset Inc and ZymoGenetics Inc.The U.S. Securities and Exchange Commission filed a parallel civil fraud case against Ramnarine.Investigators said Ramnarine learned about the takeovers while working as a director and later as an executive director in Bristol-Myers' pension and savings investment...

Read More ›

  1. Eli Lilly Net Up 7.3% on Gain

    Drug maker Eli Lilly & Co. (LLY) reported a 7% increase in third-quarter profit, as a one-time payment from a former partner helped offset an 11% sales decline drive...

  2. Eli Lilly 3rd-Quarter Net Up 7% on Gain;Gross Margins Decline

    Drug maker Eli Lilly & Co. (LLY) reported a 7% increase in third-quarter profit, as a one-time payment from a former partner helped offset an 11% sales decline drive...

  3. Eli Lilly 3rd-Quarter Net Up 7.3% on Gain; Revenue, Margins Decline

    Eli Lilly & Co.'s (LLY) third-quarter earnings rose 7.3% on a gain tied to a payment from a former partner as margins shrank amid lower-than-expected revenue.Results...

  4. EARNINGS PREVIEW: U.S. Drug Makers Struggle With Loss of Exclusivity in 3rd Quarter

    TAKING THE PULSE: Most major U.S. drug makers in the third quarter continued with efforts to cope with the recent losses of market exclusivity for former blockbuster...

  5. Icahn Reports Higher Stake in Take-Two, Lower Stake in Commercial Metals

    Carl Icahn reported in a regulatory filing late Tuesday a higher stake in video-game maker Take-Two Interactive Software Inc. (TTWO) and reduced holdings in steel ma...

  6. Eli Lilly To Record $1.26 Billion Benefit from Amylin

    Eli Lilly & Co. (LLY) revised its full-year guidance to reflect a $1.26 billion payment by Amylin Pharmaceuticals Inc. (AMLN), following the completion of Amylin's a...

  7. Eli Lilly Boosts 2012 Net Profit Forecast

    Eli Lilly and Co on Thursday raised its net profit forecast for 2012 to reflect income from the early payment of financial obligations from former partner Amylin Pha...

  8. AstraZeneca: Bristol-Myers Squibb Completes Purchase of Amylin

    AstraZeneca PLC (AZN.LN) and Bristol-Myers Squibb said Thursday that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myer...

  9. Bristol-Myers Exec Arrested for Insider Trading

    Shares of Bristol-Myers Squibb (NYSE:BMY) fell more than 7% Thursday after the drug maker halted a hepatitis C trial and U.S. officials arrested executive Robert Ram...

  10. Evercore 2nd-Quarter Profit Climbs 19% On Higher Investment Banking Revenue

    Boutique advisory firm Evercore Partners Inc. (EVR) posted a 19% rise in second-quarter earnings as the company benefited from a string of deal closings despite a to...

  11. Bristol-Myers Profit Falls 28%

    Bristol-Myers Squibb Co.'s (BMY) second-quarter profit declined 28%, as sales were eroded by recent patent expirations for top-selling drugs including the anticlotti...

  12. Icahn Sounds The Alarm on Forest Labs

    Carl Icahn has fired back at Forest Laboratories Inc.'s (FRX) board, writing another harshly worded letter despairing the company's prospects, the latest move in a l...

  1. Bristol-Myers Profit Drops 45% on Lower Heart Drug Sales

    Bristol-Myers Squibb Co. (BMY) reported a nearly 45% decline in first-quarter profit, as the loss of patent protection for formerly big-selling heart drugs continued...

  2. Bristol-Myers Net Drops on Lower Sales of Heart Drugs

    Bristol-Myers Squibb Co. (BMY) reported a nearly 45% decline in first-quarter profit, as the loss of patent protection for formerly big-selling heart drugs continued...

  3. Eli Lilly Forecasts Stronger 2013

    Eli Lilly (NYSE:LLY) reaffirmed its in-line fiscal 2012 guidance on Friday and unveiled an upbeat outlook for the following year.The company also said it continues t...

  4. S&P Likes a Trio of Biotech ETFs

    Due to increased FDA approvals and takeover speculation, biotechnology ETFs have already been among the best-performing sector funds this year, but more upside could...

  5. Bristol-Myers Posts 3rd-Quarter Loss on Hepatitis C Drug Loss, Sales Down 30%

    Bristol-Myers Squibb Co. (BMY) swung to a third-quarter loss on the costly failure of an experimental hepatitis C drug, while a steeper-than-expected drop in sales o...

  6. Bristol-Myers Sales Slump 30% on Generic Pressure

    Bristol-Myers Squibb (NYSE:BMY) reported a sharp decline in third-quarter sales and a weaker-than-expected adjusted profit on Wednesday as it continued to grapple wi...

  7. Eli Lilly Sales Slide 11% on 'Patent Cliff' Struggles

    Hurt by rising generic competition for its schizophrenia drug Zyprexa, Eli Lilly (NYSE:LLY) reported a sharp decline in sales and adjusted earnings on Wednesday, tho...

‹ Prev123Next ›
Freebase CC-BY
Source: Amylin Pharmaceuticals on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL